Medincell, a biopharmaceutical licensing company, will join the MSCI World Small Cap Index, which includes small-cap companies across 23 developed markets. This inclusion, effective November 24, 2025, is indicative of Medincell's robust business model and its commitment to innovation and social responsibility. The MSCI World Small Cap Index covers about 14% of the free-float adjusted market capitalization in each country, comprising around 3,840 stocks.
Company Profile and Operations
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Located in Montpellier, Medincell develops long-acting injectable drugs across various therapeutic areas. Its BEPO technology, which allows for controlled release of active ingredients, is notably used in the treatment of schizophrenia with the product UZEDY, approved by the FDA in 2023 and distributed in the United States by Teva. Medincell collaborates with several pharmaceutical companies and currently employs over 140 people from more than 25 nationalities.
Future Outlook and Risks
Medincell notes in its press release that statements regarding its future outlook are subject to uncertainties and risks that could cause actual results to differ materially. The company clarifies that these forecasts are based on reasonable assumptions but remain subject to various unforeseen factors beyond its control, according to regulatory requirements.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
